Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Industry report anlayzes Market for Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics By Drug Type (Corticosteroids, Immunoglobulin, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography Forecast till 2021-2028 ~Marketwatch >>>>>>>>>>>>>>>>>
The Global Autoimmune Disease Therapeutics Market size is expected to reach $149.4 billion by 2025, rising at a market growth of 4.34% CAGR during the forecast period. The autoimmune disease therapeutics market is anticipated to experience significant market growth during the forecast period due to early diagnosis of the disease, the latest launch of advanced therapy, and increased incidence of autoimmune disease. The market is witnessing a strong presence of late-stage pipeline drugs such as tocilizumab, baricitinib, olokizumab, apremilast, abatacept, PF-06438179, golimumab, ustekinumab, etrolizumab, tofacitinib, and others. On the other hand, higher costs associated with sophisticated therapy are anticipated to hamper the market growth.
Hi Changes, since VIP seems to undo damage to the myelin sheathing and regerneate nerve cell growth (which is basically impossible in conventional thinking..) I wonder wether it could substitute the need for the extremely costly Plasmapheresis treatment for autoimmune diseases? I remember you posted about IgA once before but cannot find it...
Market Data 
Markets 
AI
